Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol 3350 + electrolytes is an osmotic laxative combination used primarily for bowel cleansing prior to colonoscopy, barium enema X-ray, or other gastrointestinal procedures. The formulation consists of a high-molecular-weight polymer (PEG 3350) that acts as an osmotic agent to induce watery diarrhea, combined with a balanced mixture of electrolytes (typically sodium chloride, sodium bicarbonate, potassium chloride, and often sodium sulfate) to maintain fluid and electrolyte balance during the lavage process. This isomotic approach minimizes the net exchange of water and electrolytes across the intestinal wall, making it safer than hyperosmotic preparations for patients with renal or cardiac comorbidities. It is typically administered as a large-volume oral solution, often requiring the ingestion of up to 4 liters of fluid.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol 3350 + electrolytes.